Monte Rosa Therapeutics (GLUE) Treasury Shares (2020 - 2025)

Monte Rosa Therapeutics' Treasury Shares history runs 7 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Treasury Shares fell 98.13% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (down 98.13% YoY), while the FY2025 annual figure was $65.5 million, up 6.56% from the prior year.
• Treasury Shares for Q1 2026 stood at $1.1 million, up from $775765.0 in the prior quarter.
• The five-year high for Treasury Shares was $61.8 million in Q3 2025, with the low at $112159.0 in Q4 2024.
• The 5-year median for Treasury Shares is $49.6 million (2023), against an average of $44.1 million.
• The sharpest annual moves came in 2022 and 2024: Treasury Shares soared 16191.03% in 2022, then sank 99.78% in 2024.
• Monte Rosa Therapeutics' Treasury Shares stood at $49.3 million in 2022, then climbed by 1.66% to $50.1 million in 2023, then tumbled by 99.78% to $112159.0 in 2024, then jumped by 591.67% to $775765.0 in 2025, then surged by 48.11% to $1.1 million in 2026.
• Business Quant data shows GLUE's Treasury Shares at $1.1 million in Q1 2026, $775765.0 in Q4 2025, and $61.8 million in Q3 2025.